Please check your internet connection and try again.
Sompraz is a brand name for pantoprazole, a proton pump inhibitor (PPI).
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis
* Healing of duodenal ulcers
* Management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome
## Adult Dosing
* **GERD and Erosive Esophagitis:** 40 mg orally once daily. Duration of treatment for erosive esophagitis is typically 4 to 8 weeks.
* **Healing of Duodenal Ulcers:** 40 mg orally once daily. Treatment is usually for 10 days.
* **Pathological Hypersecretory Conditions:** The starting dose is typically 40 mg orally twice daily, but may be increased to 80 mg orally twice daily. Doses may be further increased as needed. Max dose generally considered 160 mg daily, but higher doses have been used under specialist supervision.
## Pediatric Dosing
Dosing in pediatric patients is not well-established for all indications and formulations. Consult specific pediatric guidelines or product labeling.
* **GERD (age 5 to 16 years):** 20 mg orally once daily for up to 8 weeks. Doses of 40 mg once daily have also been used.
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of rilpivirine-containing products.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use of PPIs has been associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures, hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Pantoprazole can decrease the absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may affect the metabolism of drugs such as clopidogrel.
* **Rilpivirine:** Concomitant use is contraindicated due to risk of virologic failure and potential for HIV-1 resistance.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias) especially with prolonged use.
* Consider monitoring magnesium levels in patients on long-term PPI therapy or those taking concomitant medications that may cause hypomagnesemia (e.g., diuretics).
* Monitor for signs of *Clostridium difficile* infection.
## Clinical Pearls
* Administer pantoprazole delayed-release tablets 30 minutes before a meal.
* Do not crush or chew delayed-release tablets.
* For pathological hypersecretory conditions, dose and duration should be individualized.
---
*This information is for educational purposes only and does not substitute for professional medical advice. Always verify the most current prescribing information with the official product labeling or a trusted drug reference.*
